Regentis Biomaterials (RGNT) Notes Payables (2024 - 2025)

Regentis Biomaterials' (RGNT) quarterly Notes Payables came in at $1.2 million in Q4 2025, up 108.9% year-on-year from $573000.0 in Q4 2024, and up 108.9% on a QoQ basis from $573000.0 in Q4 2024.

Regentis Biomaterials (RGNT) Notes Payables (2024 - 2025) Analysis & Trends

Regentis Biomaterials (RGNT) has 2 years of Notes Payables data on file, last reported at $1.2 million in Q4 2025.

  • On a quarterly basis, Notes Payables rose 108.9% year-over-year to $1.2 million in Q4 2025; TTM through Dec 2025 was $1.2 million, a 108.9% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 108.9% from the prior year.
  • Notes Payables for Q4 2025 stood at $1.2 million, up from $573000.0 in the prior quarter.
  • Over the last five years, Notes Payables for RGNT reached as high as $1.2 million in Q4 2025 and fell as low as $573000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alcon 32,734,969.19 Bn 32,734,967.53 Bn 1.53 Bn
2 Intuitive Surgical 117.50 Bn 112.41 Bn 1.96 Bn
3 Becton Dickinson 42.93 Bn 42.11 Bn 2.15 Bn
4 Medline 30.82 Bn 36.66 Bn 1.84 Bn
5 Resmed 27.90 Bn 26.23 Bn 890.98 Mn
6 West Pharmaceutical Services 26.76 Bn 26.23 Bn 329.20 Mn
7 Cooper Companies 15.30 Bn 15.16 Bn 735.40 Mn
8 Solventum 13.46 Bn 12.90 Bn 1.10 Bn
9 Align Technology 12.02 Bn 10.96 Bn 736.59 Mn
10 Regentis Biomaterials 1.10 Mn -6.28 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.20 Mn
Dec 31, 2024 573,000.00